COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units

NCT ID: NCT04433325

Last Updated: 2020-06-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-30

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since early 2020, France knows a sanitary crisis with a massive influx of COVID-19 patients admitted in Intensive Care Units (ICU). It led to a saturation of the French health system, especially in some geographic areas such as East of France or Paris region. Therefore, authorities decided to transfer some critically ill patients from these crowded ICUs to less busy regional ICUs. it was done for the first time by medical train transportation. Knowing that the investigators lack experience regarding this type of medical evacuation, regarding the high number of transferred patients, with such a logistic effort, the investigators decided to study this phase of the COVID-19 sanitary crisis in order to draw a feedback. So far, there are no data in the literature regarding this topic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Intensive Care Unit Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients transferred

Patients transferred from Paris's Intensive Care Units

No interventions assigned to this group

Patients not transferred

Patients admitted in Intensive Care Units with no transfer from Paris

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* COVID-19 positive patients admitted in Intensive Care Unit between 15/03/2020 and 15/04/2020
* Patients (or legal representative) with no opposition to inclusion in medical research protocol
* Regarding case group : Patients transferred from Paris's ICU
* Regarding case control group : Patients admitted in ICU with no transfer from Paris

Exclusion Criteria

\- \> 18 years under legal protection and patients with liberty restriction
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benoît Painvin

Role: PRINCIPAL_INVESTIGATOR

CHU Rennes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Poitiers

Poitiers, , France

Site Status

CHU Tours

Tours, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nicolas Mevel

Role: CONTACT

0299282555

Anne Ganivet

Role: CONTACT

0299282555

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Arnaud THILLES

Role: primary

Stéphane ERHMANN

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35RC20_3091_TOCCIP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.